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Abstract
Background: Feeding related peptides have been shown to be additionally involved in the central
autonomic control of gastrointestinal functions. Recent studies have shown that ghrelin, a stomach-
derived orexigenic peptide, is involved in the autonomic regulation of GI function besides feeding
behavior. Pharmacological evidence indicates that ghrelin effects on food intake are mediated by
neuropeptide Y in the central nervous system.
Methods: In the present study we examine the role of ghrelin in the central autonomic control of
GI motility using intracerobroventricular and IP microinjections in a freely moving conscious rat
model. Further the hypothesis that a functional relationship between NPY and ghrelin within the
CNS exists was addressed.
Results: ICV injections of ghrelin (0.03 nmol, 0.3 nmol and 3.0 nmol/5 µl and saline controls)
decreased the colonic transit time up to 43%. IP injections of ghrelin (0.3 nmol – 3.0 nmol kg-1 BW
and saline controls) decreased colonic transit time dose related. Central administration of the
NPY1 receptor antagonist, BIBP-3226, prior to centrally or peripherally administration of ghrelin
antagonized the ghrelin induced stimulation of colonic transit. On the contrary ICV-pretreatment
with the NPY2 receptor antagonist, BIIE-0246, failed to modulate the ghrelin induced stimulation of
colonic motility.
Conclusion: The results suggest that ghrelin acts in the central nervous system to modulate
gastrointestinal motor function utilizing NPY1 receptor dependent mechanisms.
Background
The presence or absence of food in the gut stimulates the
release of several regulatory peptides. These orexigenic
(NPY, AGRP, ghrelin, MCH, Orexin-A, ...) and anorexi-
genic (CRF, CCK, CART, GLP-1, leptin, insulin, ...) pep-
tides participating in the hypothalamic control of feeding
behavior and satiety have been shown to be additionally
involved in the autonomic control of gastointestinal (GI)
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functions like secretion and motility. For example fasted
motor activity of the GI tract, e.g. the colon, is observed
after intracerebroventricular (ICV) injection of neuropep-
tide Y whereas CRF ICV-treatment cause the disruption of
fasted colonic motor activity [1]. Stomach-derived ghrelin
is the first peripheral orexigenic peptide identified [2-6].
There is convincing evidence from several groups of inves-
tigators that ghrelin acts in the CNS and the periphery to
simulate not only feeding but also GI function such as gas-
tric acid secretion and gastric motility in rodents [7,9-11].
However, it is still unknown whether ghrelin is involved
in the CNS control of other digestive functions besides
gastric acid secretion and motility. Recent studies suggest
that CNS-signaling by circulating ghrelin is mediated
downstream by neurons of arcuate nucleus and the par-
aventricular nucleus of the hypothalamus, in particular,
neurons expressing neuropeptide Y and agouti-related
protein (AGRP) [12-14]. Furthermore it has been demon-
strated that there is an anatomical interaction and func-
tional relationship between ghrelin and neuropeptide Y.
Using electrophysiological recordings Cowley et al have
found that ghrelin stimulated the activity of arcuate NPY-
ergic neurons and mimicked the effect of NPY in the par-
aventricular nucleus of the hypothalamus [15]. In
addition ghrelin simulates food intake through hypotha-
lamic NPY1 receptors [1,16,17]. Thus, the question came
up "are NPY receptors involved in the ghrelin effect on GI
function"? Among others, neuropeptide Y plays a role in
the CNS control of gastrointestinal function [1,18]. NPY
activates at least six receptor subtypes, NPY1 to NPY6. NPY
binds preferentially with high affinity to Y1 and Y2 recep-
tors, and there is evidence suggesting that these two recep-
tor subtypes are involved in CNS regulation of digestive
function by NPY action in arcuate nucleus and the par-
aventricular nucleus of the hypothalamus [18].
Taken together there is overwhelming evidence that ghre-
lin, beside its satiety modulatory capacity, is involved in
the CNS control of digestive function of the upper gas-
trointestinal tract. In the CNS ghrelin and NPY, the most
potent orexigenic neuropeptides known, are anatomical
associated and functionally related. Moreover hypotha-
lamic NPYergic neurons are downstream mediators of
feeding related ghrelin action.
In the present study we scrutinize the hypothesis that cen-
tral neuropeptide Y receptor activation is involved in the
ghrelin induced modulation of gastrointestinal motility
using a microinjection-model in conscious fed and freely
moving rats.
Methods
Animals
All experimental components described were performed
in accordance with the requirements of German legisla-
tion for the protection of animals and were licensed and
supervised by the appropriate government body.
Male Sprague-Dawley rats with a mean body weight of
350 ± 50 g were maintained on a 12 : 12 h photoperiod.
They were housed in colony cages under conditions of
controlled humidity and temperature (22 ± 2°C) for at
least 7 days prior to the surgical procedure. The animals
were fed a standard rat diet (Altromin®, Lage, Germany)
an tap water ad libitum. After surgical procedures, rats were
housed individually. During experimental procedure the
animals had continuous access to food and water.
Drugs
Ghrelin (Bachem, Heidelberg, Germany) doses of 0.03
nmol (100 ng), 0.3 nmol (1 µg) and 3 nmol (10 µg)/5 µl
were dissolved in 0.15 M sterile saline (B. Braun, Melsun-
gen, Germany). The NPY1 receptor antagonist, BIBP-3226
(200 nmol/5 µl; Sigma-RBI, Natrick, MA, USA) [see Ref.:
[19]] and the NPY2 receptor antagonist, BIIE-0246 (120
nmol/5  µl; Boehringer-Ingelheim, Biberach, Germany)
[see Ref.: [21]] were dissolved in sterile 0.15 M saline. The
NPY receptor antagonists were used in similar equipotent
nanomolar concentrations. The used intracerebroven-
tricular concentrations of the receptor antagonists were
comparable with the ICV-dosages used by other groups in
rodents [18,20]. Probes were aliquoted and frozen (-
80°C). Fresh aliquots were thawed on each experimental
day before injections. Any excess was discarded. In our
hands nanomolar concentrations of BIBP-3226 and BIIE-
0246 were effective in antagonization of NPY receptor
subtypes without any side effects. In particular no central
depressive effects or conspicuous behavior was observed
after BIBP-3226 treatment [18].
Cerebral cannulas
For surgical procedures, rats were anesthetized with a mix-
ture of ketamine (75 mg kg-1 i.p., Parke-Davis, Freiburg,
Germany) and xylazine (5 mg kg-1  i.p., Bayer AG,
Leverkusen, Germany). Animals were positioned in a ster-
eotactic apparatus (David Kopf Instruments, Tujunga,
CA). The head was fixed in a nose-down-position (-3 mm)
and the skull exposed. Then trepanation of the skullcap
was performed according to coordinates obtained from
Paxinos and Watson [22] (mm from bregma: anterior-
posterior = -3.30; lateral = ± 0.0; dorsoventral = -3.8).
According to these coordinates a 22-gauge guide cannula
(Bilarney / Plastic one, Düsseldorf, Germany) was
implanted into the third ventricle. The cannula was
anchored by dental cement and stainless steel screws
affixed to the skull. Dummy cannulas (28 G), extending 2
mm beyond the guide cannula tips, were inserted to pre-
vent blockage. After cerebral surgery, animals were indi-
vidually housed. The animals were allowed 4 daysBMC Gastroenterology 2005, 5:5 http://www.biomedcentral.com/1471-230X/5/5
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recovery after guide cannula surgeries before the abdomi-
nal surgical procedures were performed.
Colonic catheter
This method was performed as described elsewhere [1].
Prior to all abdominal surgeries, the animals were food
deprived overnight. Four days after cerebral surgery, rats
were anaesthetized with a mixture of ketamine (75 mg kg-
1) and xylazine (5 mg kg-1). After laparatomy a polyethyl-
ene microcatheter (inside diameter, 1.2 mm; outside
diameter 1.7 mm; Becton Dickinson, New Jersy, USA) was
chronically implanted into the proximal colon 1 cm distal
from the caecocolonic junction. The catheter was fixed at
the colonic wall by a purse-string suture and routed sub-
cutaneously to the interscapular region, where it was exte-
riorized through the skin and secured. The animals were
allowed 7 days recovery after abdominal surgeries before
the beginning of habituation training sessions. Experi-
ments were performed in fed, conscious rats.
Intraperitoneal (IP) and intracerebroventricular (ICV) 
microinjection
The doses of ghrelin were calculated according to the low-
est effective doses to stimulate food intake [see Ref.: [23]].
For IP injection a 1 ml syringe (Hamilton, Reno, NV, USA)
was used. Ghrelin and vehicle were injected IP after cen-
tral administration of vehicle or NPY receptor antagonist.
For IP injections the low dose of ghrelin administered
peripherally was 0.3 nmol kg-1/1 ml 0.15 M saline and the
high dose of ghrelin was 3 nmol kg-1/1 ml saline. NPY
receptor antagonists were injected ICV 15 min before
ghrelin was given peripherally at doses of 200 nmol/rat
(BIBP-3226) and 120 nmol/rat (BIIE-0246) respectively.
For ICV injections a 1 µl micro syringe (Hamilton, Reno,
NV, USA), attached to a 32 G injection needle via a PE-50
tube-catheter was used. The stainless steel injection can-
nulas (32 G) were cut to protrude 2 mm beyond the tips
of the guide cannulas. The conscious animals were gently
restrained by hand, the injection needle was inserted
through the guide cannula, and vehicle (5 µl 0.15 M
saline) or NPY receptor antagonists (BIBP-3226 200
nmol/5 µl; BIIE-0246 120 nmol/5 µl) and ghrelin (0.03
nmol, 0.3 nmol or 3 nmol/5 µl), were consecutively
injected ICV slowly over a 60 s period. We used a 15 min
time interval between ICV injection of receptor antagonist
or vehicle and ICV ghrelin administration. The injection
needle was left in place for 2 min after injection to allow
diffusion of the solution and to prevent back flow. Then
dummy cannulas were reinserted into the guide cannulas.
After the last experimental testing session, the rats were
anesthetized and 5 µl of alcian blue 8GX were injected
ICV.
Colonic transit time measurement
Colonic transit time was calculated by using an enteral
dye-marker. Trypan blue, a non-absorbable dye, was
injected in 0.2 ml volume through the catheter positioned
in the proximal colon and followed by a 0.2 ml saline
flush immediately after the ICV or IP microinjection.
Colonic transit time was evaluated as the time interval
between dye injection and the discharge of the first blue
pellet. Faecal pellet output was monitored continuously
by a self-developed, automated observation system that
mechanically registers the time of all bowel movements
for 24 h. The device consists of a conveyor belt placed
under the mesh bottom cage, which transports faecal pel-
lets with defined velocity to a collector.
Brain histology
The methods were performed as described in previous
studies [17]. When experiments were completed, rats were
anaesthetized with ketamine (75 mg kg -1 i.p.) and xyla-
zine (5 mg kg -1 i.p.), and 0.05% alcian blue 8GX was
microinjected intracerebroventricular under the same
conditions as vehicle or peptide. The anaesthetized ani-
mals were transcardially perfused with phosphate buff-
ered saline (PBS) buffer (0.1 M, pH 7.4) followed by
Zamboni's fixative (2% formaldehyde and 2% picric acid
in 0.1 M PBS buffer, pH 7.4). The brains were removed
and cryoprotected in 25% sucrose. The site of injection
was confirmed by inspection of intracerebroventricular
dye distribution. Animals that received injections outside
of the 3rd ventricle were excluded from data analysis.
Experimental design
Experiment I: Effect on colonic motorfunction of peripheral (IP) and 
central (ICV) ghrelin administration
The aim of the first experiment was to determine whether
exogenous ghrelin would alter colonic motor function.
Thus in experiment I, dose response effects of ghrelin in
the cerebrospinal fluid (ICV) and the periphery (IP) on
colonic transit time were examined. Ghrelin or saline as a
vehicle was administered ICV or IP in conscious lightly
restrained rats as previously described. For IP injection the
low dose of ghrelin administered peripherally was 0.3
nmol kg-1 BW and the high dose of ghrelin was 3.0 nmol
kg-1 BW. After injections, rats were subsequently returned
to their home cages and maintained in a non-stressful
environment to monitor colonic transit time. In order to
minimize interindividual variation, and to reduce the
number of animals needed to perform this study, animals
were tested twice in this study. In randomized order, each
rat received vehicle and a single dose of ghrelin or vehicle
ICV or IP. The time interval between the experiments per-
formed on the same animal was at least 4 days.BMC Gastroenterology 2005, 5:5 http://www.biomedcentral.com/1471-230X/5/5
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Experiment II: Effect of BIBP-3226 and BIIE-0246 pretreatment on 
centrally and peripherally injected ghrelin induced modulation of 
colonic transit
In experiment II the hypothesis that ghrelin acts at the
CNS to modulate colonic motor function via a NPY recep-
tor dependent pathway was addressed. Therefore, we
determined if a pretreatment with selective NPY1- (BIBP-
3226) and NPY2 (BIIE-0246) receptor antagonists admin-
istered into the cerebrospinal fluid would block the alter-
ations of colonic motor activity induced by centrally and
peripherally administered ghrelin. The animals were pre-
treated with the NPY-Y1  and -Y2  receptor antagonists,
injected ICV or vehicle (0.15 M saline), 15 min prior to
ICV or IP ghrelin injections. Thereafter colonic transit
time was assessed as described above.
Data analysis
The criterion used to include results in the data analysis of
the ICV-injected group was the correct placement of the
ICV cannulas.
Results are expressed as mean ± SEM. The data of all stud-
ies were analyzed by ANOVA and differences between
groups were evaluated by the Student-Newmann-Keuls
test. P < 0.05 was considered significant.
Results
Effect of peripherally (IP) and centrally (ICV) administered 
ghrelin on colonic motor function
In experiment I, dose response effect of peripherally and
centrally administered ghrelin on colon transit time in fed
and freely moving rats were examined. As demonstrated
in Fig. 1, ghrelin injected into the cerebrospinal fluid
(CSF) stimulates colonic transit time dose dependently. In
rats microinjected with vehicle into the CSF or IP, the
average colonic transit time was 322 ± 8 min. As demon-
strated in Fig. 1, 0.03 nmol, 0.3 nmol and 3 nmol/5 µl
ghrelin injected ICV dose-dependently decreased transit
time by 24%, 34% and 43% respectively in conscious fed
rats. Peripherally administered ghrelin accelerated transit
time up to 36% (Fig. 1).
Effect of ICV NPY receptor antagonist pretreatment on 3rd 
ventricular and peripherally ghrelin induced stimulation of 
colonic transit
The hypothesis that ghrelin acts in the brain to stimulate
colonic transit via NPY receptor dependent mechanisms
was addressed. As shown in Fig. 2, pre-treatment with
BIBP-3226 (200 nmol) which is a selective NPY1 receptor
antagonist 15 min prior to ICV application of 0.3 nmol
ghrelin totally blocked the ghrelin induced effect on
colonic transit. Application of BIBP-3226 into the CSF of
the control group that was microinjected with vehicle, had
no effect. Changes in colonic transit time induced by IP
injection of ghrelin (3.0 nmol kg-1 BW) were canceled by
ICV injection of NPY1 receptor antagonist, BIBP-3226.
(Fig.: 2). Pretreatment with the selective NPY2 receptor
antagonist, BIIE-0246, failed to affect the ghrelin induced
alteration of colonic transit time. (Fig.: 2)
Discussion
The present experiments using a freely moving conscious
rat model permit the measurement of colonic motility in
rats in the physiological fed status. The results demon-
strated that ghrelin given ICV and IP stimulates gastroin-
testinal motility indicated by shortened colonic transit
time. In addition we found that the NPY type 1 receptor is
primarily involved in the ghrelin induced modulation of
fasted motor activity of the colon.
There is convincing evidence that the most effective appe-
tite stimulating peptides, NPY and ghrelin, act in the CNS
and the periphery to simulate not only feeding but also GI
function such as gastric acid secretion and gastric motility
[1,8-10]. Stomach derived ghrelin, first described in 1999
by Kojima et al., is the first peripheral orexigenic peptide
identified [4]. Ghrelin was identified as endogenous lig-
and for the GH secretagogue receptor (GHS R) and a
peripheral metabolic signal informing the brain about
stomach nutrient load [17,24]. Physiological studies sug-
gest a functional relationship of ghrelin and NPY within
the brain. It has been demonstrated that peripherally (i.v.)
and central (ICV) administered ghrelin increases the
expression of the immediate early gene c-fos, a marker of
neuronal activity, in the arcuate nucleus and the PVN in
awake fed rats [25]. Furthermore, exogenous ghrelin
increases mRNA levels for NPY into the arcuate nucleus
and simulates food intake through hypothalamic NPY1
receptors [14,16,26]. Further Fujino et al. have demon-
strated that ICV pretreatment with neuropeptide Y antise-
rum completely blocked ghrelin induced gastric and
duodenal motoractivity [9]. Taken together these data
suggest that there is an anatomical interaction and func-
tional relationship between ghrelin and NPY within the
brain. Six recognized subtypes of neuropeptide Y recep-
tors have been described (NPY1 to NPY6). Two of these,
NPY1- and NPY2 receptors, are found in high density in
the hypothalamus. There is compelling evidence that, in
particular, NPY1 and NPY2 receptors are involved in the
CNS regulation of gastrointestinal function. [1,8,27] For
this reason, we focused on neuropeptide Y1 and Y2 recep-
tor pathways in the present study and did not investigate
the role of neuropeptide Y receptor subtypes Y4 and Y5
which are also expressed in the hypothalamus and are also
involved in the autonomic control of feeding behavior
and GI function. In the present study pretreatment with
the NPY1 receptor antagonist, BIBP-3226, blocked stimu-
lation of colonic motility induced by systemic microinjec-
tion of exogenous ghrelin (ICV and IP). In our hands BIIE-
2046, which is a selective antagonist of the NPY Y2 recep-BMC Gastroenterology 2005, 5:5 http://www.biomedcentral.com/1471-230X/5/5
Page 5 of 8
(page number not for citation purposes)
tor, failed to affect the ghrelin induced induction of fasted
motor activity. It was previously described that knocking
out NPY significantly decreases ghrelin stimulated feeding
[17,28]. In this context Fujino et al. have recently demon-
strated that the ghrelin induced fasted gastroduodenal
motor activity in rats is blocked by ICV injection of GHS-
R antagonist as well as NPY antiserum [9]. The results pre-
sented by Fujino et al. also suggest that the vagal pathway
may mediate the action of centrally administered ghrelin
on gastroduodenal motility [9]. Thus we can speculate
that central NPY pathways, e.g. centrally NPY receptor
activation, are the primary downstream mediator of circu-
lating ghrelin. This interpretation is consistent with neu-
roanatomical and physiological facts: Neuropeptide Y
works at two sites, locally within the arcuate nucleus to
inhibit POMC neuronal activity and at afferent-terminal
sites, in particular the paraventricular nucleus of the
hypothalamus. Guan et al. have shown that neuropeptide
Y- and ghrelin like immunoreactive (LI) neurons within
the arcuate nucleus could influence each other by com-
plex synaptic transmissions [29]. Furthermore Cowley et
al. have demonstrated that ghrelin stimulated the activity
of arcuate neuropeptide Y-LI neurons and mimicked the
effect of neuropeptide Y in the PVN [15]. Compelling evi-
dence showed that NPY projections from the arcuate
nucleus (ARC) to the PVN are involved in the CNS regula-
tion of food intake and other physiological functions of
the organism, e.g. digestive function, by neuroendocrine
and autonomic pathways [17,18]. For example NPY
released from ARC neurons activates NPY-Y1 receptors in
the hypothalamus, e.g. the PVN, and results in the stimu-
lation of GI motor function [18]. Furthermore arcuate
Effect of ghrelin injected into the 3rd ventricle (ICV) and intraperitoneally (IP) on colonic transit time Figure 1
Effect of ghrelin injected into the 3rd ventricle (ICV) and intraperitoneally (IP) on colonic transit time. Ghrelin injected ICV as 
well as IP induced a dosed-related stimulation of propulsive colonic motor activity. MI = microinjection The bars represent the 
mean ± SEM. * P < 0.05 vs. vehicle. ■  = vehicle-group; A = 0.03 nmol ghrelin /5 µl 0.15 M saline; B = 0.3 nmol ghrelin /5 µl 0.15 
M saline; C = 3 nmol ghrelin /5 µl 0.15 M saline; D = 0.3 nmol ghrelin kg-1 BW; E = 3.0 nmol ghrelin kg-1 BW
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NPYergic neurons have been thought to regulate feeding
behavior by NPY receptor subtypes Y1 and Y5 in the PVN
and adjacent areas [17]. Pretreatment with a Y1, but not
other receptor antagonist markedly inhibited ghrelin-
induced feeding, pointing to NPY receptor Y1 as one of
the downstream pathways [9,17]. With regard to the char-
acteristic physiological feature that peripheral ghrelin
does not cross the blood-brain barrier in rodents it is
important to note that the arcuate nucleus is the only
hypothalamic structure located outside the brain-blood
barrier [30]. Thus we can speculate that circulating ghrelin
modulates gastrointestinal motility via  activation of
hypothalamic, in particular by using NPYergic pathways
via activation of NPY-Y1 receptors, in the arcuate nucleus.
This hypothesis is in good agreement with our observa-
tion that the effect of peripherally (IP) administered ghre-
lin on colonic motility is blocked by ICV pretreatment
with the specific NPY1 receptor antagonist, BIBP-3226.
The NPY2 receptor antagonist BIIE-0246 injected in the 3rd
ventricle at the equipotent dose as BIBP-3226 was not
effective to antagonize the ghrelin effect on GI motility
significantly. This data suggests that ghrelin unfolds a
stimulatory effect on colonic motility primarily by acting
on central NPY1 and not via NPY2 receptors. This interpre-
tation is confirmed by the observation that Y1 receptors
acts rather postsynaptically and the Y2 receptor rather pre-
Effect of pretreatment with NPY receptor antagonists on fasted motor activity of the colon induced by centrally (ICV) and  peripherally (IP) administered ghrelin Figure 2
Effect of pretreatment with NPY receptor antagonists on fasted motor activity of the colon induced by centrally (ICV) and 
peripherally (IP) administered ghrelin. BIBP-3226, which is a selective NPY Y1 receptor antagonist, injected ICV antagonizes the 
stimulation of colonic transit induced by ghrelin injected in the same route and IP. The NPY Y2 receptor antagonist BIIE-2046 
injected ICV fails to affect the stimulated colonic motoractivity induced by ICV or IP injection of ghrelin. MI = microinjection 
The bars represent the mean ± SEM. * P < 0.05 vs. vehicle-group; #P < 0.05 vs. ghrelin-group
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synaptically [31,32] The question of whether neuropep-
tide Y4 or Y5 receptors in the CNS are involved in the CNS
control of gastrointestinal function should be examined
in future studies.
Conclusion
We hypothesize that circulating ghrelin exhibits its effect
by activating hypthalamic neurons, in particular neurons
in the arcuate nucleus bearing GHS- and NPY-Y1 recep-
tors. Further this ghrelin induced neuronal activation
leads to stimulation of GI motor function by activation of
higher hypothalamic brain sites, e.g. activation of neuro-
nal projections within the paraventricular nucleus of the
hypothalamus. On the other hand it is possible that the
site of action of circulating ghrelin is not the hypothala-
mus but other brain sites. In our model using 3rd ventricu-
lar injection of ghrelin this could simply mean that the
peptide gained access to the 4th ventricle and reached fur-
ther caudal brain sites, e.g. NTS, DVC and medulla oblon-
gata. With respect to the distribution of GHS- and NPY
receptors in the CNS this hypothesis is possible, but how
ghrelin action on any of these brain sites would modulate
digestive function is not known. This question should be
examined in future studies
In summary, we presented evidence that ghrelin is
involved in the CNS control of GI function. Apart from
humoral pathways ghrelin acts into the CNS to control GI
function by a mechanism of action involving neuropep-
tide Y1 receptor pathways. Further this study support the
hypothesis giving by Chen et al. that ghrelin has an abso-
lute requirement for neuropeptide Y pathways to unfold
its physiological effects [28].
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